Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in patients with relapsing-remitting multiple sclerosis (CombiRx).

Trial Profile

A multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in patients with relapsing-remitting multiple sclerosis (CombiRx).

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs Glatiramer acetate (Primary) ; Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms CombiRx; MS-CombiRx
  • Most Recent Events

    • 12 Oct 2018 Results assessing baseline cerebellar volume as predictor of disability in MS (n=838) presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 23 Mar 2013 Results after a mean time on study of 3.9 years presented at the 65th Annual Meeting of the American Academy of Neurology.
    • 23 Mar 2013 Interim (4-year) results presented at the 65th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top